OPTIMER PHARMACEUTICALS INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 10 rows in 2012. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2012-07-23: Reporting owner Newman Stephen L; Form 4; Security Stock option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2012-06-29: Reporting owner Webster Stephen W; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2012-06-11: Reporting owner CHANG JOSEPH Y; Form 4; Security Stock option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2012-02-07: Reporting owner Shue Youe Kong; Form 4; Security Stock option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2012-07-23 | Newman Stephen L Director | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $14.01 exercise price | 2012-07-24 | |
| 2012-06-29 | Webster Stephen W Officer (CFO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $15.46 exercise price | 2012-07-02 | |
| 2012-06-11 | CHANG JOSEPH Y Director | 4 | Stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,461 0 owned after | $0.65 exercise price | 2012-06-20 | |
| 2012-02-07 | Shue Youe Kong Officer (VP, Clinical Development) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,000 4,000 owned after | $13.51 exercise price | 2012-02-09 | |
| 2012-02-07 | Papaz Gregory E. Officer (SVP, Commercial Operations) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,750 18,750 owned after | $13.51 exercise price | 2012-02-09 | |
| 2012-02-07 | Hartman Kurt M Officer (Gen. Counsel, Chief Compliance) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,750 18,750 owned after | $13.51 exercise price | 2012-02-09 | |
| 2012-02-07 | Gorbach MD Sherwood Officer (SVP, Chief Medical Officer) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,320 24,320 owned after | $13.51 exercise price | 2012-02-09 | |
| 2012-02-07 | AMPER LINDA E Officer (SVP, Human Resources) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +18,750 18,750 owned after | $13.51 exercise price | 2012-02-09 | |
| 2012-02-07 | LICHTINGER PEDRO Director, Officer (CEO and President) | 4 | stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +120,000 120,000 owned after | $13.51 exercise price | 2012-02-09 | |
| 2012-02-07 | Prunty John D Officer (CFO and SVP, Finance) | 4 | Stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $13.51 exercise price | 2012-02-09 |